Showing 131 - 140 of 11,585
Background: What constitutes innovation in health technologies can be defined and measured in a number of ways and it has been widely researched and published about. However, while many countries mention it as a criterion for pricing or reimbursement of health technologies, countries differ...
Persistent link: https://www.econbiz.de/10012804110
Persistent link: https://www.econbiz.de/10011977899
Background: The necessity to measure and reward "value for money" of new pharmaceuticals has become central in health policy debates, as much as the requirement to assess the "willingness to pay" for an additional, qualityadjusted life year (QALY). There is a clear need to understand the...
Persistent link: https://www.econbiz.de/10012291180
Objective This study compared the clinical efficacy and cost-effectiveness of parenteral iron, using intravenous iron sucrose (IVIS) therapy against the standard regimen of oral iron (OI) therapy for managing iron-deficiency anemia (IDA) among pregnant women in a natural primary care setting in...
Persistent link: https://www.econbiz.de/10015358180
Persistent link: https://www.econbiz.de/10013279206
Persistent link: https://www.econbiz.de/10013279337
Persistent link: https://www.econbiz.de/10013431754
Persistent link: https://www.econbiz.de/10013392039
The passage of the UHC law in 2019 mandated the creation of the Health Technology Assessment (HTA) Program to identify and recommend the most cost-effective health technologies for the Philippine government to procure. Since its inception, the HTA has mostly assessed COVID-19 related...
Persistent link: https://www.econbiz.de/10014475399
Health technology assessment (HTA) is a comprehensive and structured evaluation that aims to analyze the potential impacts of health technologies, including medical devices, diagnostic tools, pharmaceuticals, and public health interventions. Its purpose is to provide policymakers with...
Persistent link: https://www.econbiz.de/10014500317